Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker SRPT · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular D… NCT07542314 · Duchenne Muscular Dystrophy ELEVIDYS, Sirolimus | SRPT Sarepta Therapeutics, Inc. | Phase 4 | Recruiting | 20 | Aug 31, 2027 | Registry ↗ |
| Nov 10, 2026 | Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administered by Systemic Infus… NCT06747273 · Limb Girdle Muscular Dystrophy, Limb Girdle Muscular Dystro… SRP-9004 | SRPT Sarepta Therapeutics, Inc. | Phase 1 | Terminated | 4 | Jun 18, 2025 | Registry ↗ |
| Nov 10, 2026 | A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory P… NCT05906251 · Limb Girdle Muscular Dystrophy SRP-6004 | SRPT Sarepta Therapeutics, Inc. | Phase 1 | Terminated | 2 | Jun 13, 2025 | Registry ↗ |
| Nov 10, 2026 | A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Mu… NCT03992430 · Muscular Dystrophy, Duchenne Eteplirsen | SRPT Sarepta Therapeutics, Inc. | Phase 3 | Completed was active, not recruiting | 160 | Sep 7, 2026 | Registry ↗ |
| Nov 6, 2026 | A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (… NCT06241950 · Duchenne Muscular Dystrophy delandistrogene moxeparvovec, imlifidase | SRPT Sarepta Therapeutics, Inc. | Phase 1 | Terminated | 5 | Oct 10, 2025 | Registry ↗ |
| Nov 2, 2026 | A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinica… NCT06606340 · Duchenne Muscular Dystrophy Eteplirsen, Golodirsen | SRPT Sarepta Therapeutics, Inc. | — | Enrolling by invitation | 300 | Dec 31, 2033 | Registry ↗ |
| Oct 23, 2026 | An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care in P… NCT06270719 · Duchenne Muscular Dystrophy Delandistrogene Moxeparvovec, Standard of Care | SRPT Sarepta Therapeutics, Inc. | — | Enrolling by invitation | 500 | Dec 31, 2028 | Registry ↗ |
| Oct 19, 2026 | A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease NCT07536061 · Huntington's Disease SRP-1005, Placebo | SRPT Sarepta Therapeutics, Inc. | Phase 1 | Recruiting | 32 | Nov 30, 2027 | Registry ↗ |
| Oct 5, 2026 | Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy NCT06138743 · Myotonic Dystrophy 1 SRP-1003 IV Infusion, Placebo IV Infusion | SRPT Sarepta Therapeutics, Inc. | Phase 1/2 | Enrolling by invitation | 78 | Dec 31, 2026 | Registry ↗ |
| Oct 5, 2026 | Study of SRP-1001 in Adult and Adolescent Participants With Facioscapulohumeral Muscular Dystrophy… NCT06131983 · Muscular Dystrophy, Facioscapulohumeral SRP-1001 for Injection, Placebo | SRPT Sarepta Therapeutics, Inc. | Phase 1/2 | Enrolling by invitation | 60 | Dec 31, 2028 | Registry ↗ |
| Sep 11, 2026 | A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxepar… NCT04626674 · Duchenne Muscular Dystrophy delandistrogene moxeparvovec | SRPT Sarepta Therapeutics, Inc. | Phase 1 | Recruiting | 83 | Dec 31, 2027 | Registry ↗ |
| May 22, 2026 | A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (… NCT05881408 · Duchenne Muscular Dystrophy delandistrogene moxeparvovec, placebo | SRPT Sarepta Therapeutics, Inc. | Phase 3 | Active, not recruiting | 148 | May 31, 2027 | Registry ↗ |
| Mar 2, 2026 | A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9… NCT06246513 · Limb-girdle Muscular Dystrophy SRP-9003, Glucocorticoid | SRPT Sarepta Therapeutics, Inc. | Phase 3 | Active, not recruiting | 17 | Mar 4, 2025 | Registry ↗ |
| Feb 19, 2026 | A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in… NCT05876780 · Limb Girdle Muscular Dystrophy SRP-9003 | SRPT Sarepta Therapeutics, Inc. | Phase 1 | Active, not recruiting | 6 | Aug 28, 2028 | Registry ↗ |
| Feb 6, 2026 | A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in… NCT05967351 · Duchenne Muscular Dystrophy delandistrogene moxeparvovec | SRPT Sarepta Therapeutics, Inc. | Phase 3 | Enrolling by invitation | 400 | Oct 31, 2033 | Registry ↗ |
| Jan 20, 2026 | Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-… NCT03652259 · Limb-Girdle Muscular Dystrophy, Type 2E SRP-9003 | SRPT Sarepta Therapeutics, Inc. | Phase 1/2 | Terminated | 6 | Jan 14, 2025 | Registry ↗ |
| Nov 18, 2025 | Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dys… NCT02500381 · Duchenne Muscular Dystrophy SRP-4045, SRP-4053 | SRPT Sarepta Therapeutics, Inc. | Phase 3 | Completed | 228 | Nov 12, 2024 | Registry ↗ |
| Nov 6, 2025 | A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1… NCT04475926 · Limb-girdle Muscular Dystrophy | SRPT Sarepta Therapeutics, Inc. | — | Active, not recruiting | 205 | Sep 5, 2030 | Registry ↗ |
| Sep 4, 2025 | A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-90… NCT06597656 · Duchenne Muscular Dystrophy delandistrogene moxeparvovec, Plasmapheresis | SRPT Sarepta Therapeutics, Inc. | Phase 1 | Terminated | 3 | Aug 5, 2025 | Registry ↗ |
| Aug 6, 2025 | A Study of SRP-9005 in Limb Girdle Muscular Dystrophy Type 2C/R5 Pediatric and Adult Participants NCT06952686 · Muscular Dystrophies, Limb-Girdle SRP-9005, Corticosteroid | SRPT Sarepta Therapeutics, Inc. | Phase 3 | Withdrawn | 0 | Nov 30, 2030 | Registry ↗ |
| Jul 8, 2025 | A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (… NCT05096221 · Duchenne Muscular Dystrophy delandistrogene moxeparvovec, placebo | SRPT Sarepta Therapeutics, Inc. | Phase 3 | Completed | 126 | Oct 4, 2023 | Registry ↗ |
| Mar 10, 2025 | Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Expansion (P… NCT04004065 · Duchenne Muscular Dystrophy Vesleteplirsen | SRPT Sarepta Therapeutics, Inc. | Phase 2 | Terminated | 62 | Oct 30, 2023 | Registry ↗ |
| Nov 14, 2024 | A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for… NCT03769116 · Muscular Dystrophy, Duchenne delandistrogene moxeparvovec, placebo | SRPT Sarepta Therapeutics, Inc. | Phase 1/2 | Completed | 41 | Dec 8, 2020 | Registry ↗ |
| Nov 14, 2024 | A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in… NCT03375164 · Duchenne Muscular Dystrophy delandistrogene moxeparvovec | SRPT Sarepta Therapeutics, Inc. | Phase 1/2 | Completed | 4 | Apr 25, 2023 | Registry ↗ |
| Sep 19, 2024 | An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Stu… NCT03675126 · Muscular Dystrophy, Duchenne SRP-5051 | SRPT Sarepta Therapeutics, Inc. | Phase 1/2 | Terminated | 15 | Aug 25, 2021 | Registry ↗ |
| Sep 19, 2024 | An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy NCT03532542 · Duchenne Muscular Dystrophy Casimersen, Golodirsen | SRPT Sarepta Therapeutics, Inc. | Phase 3 | Terminated | 171 | Jul 26, 2023 | Registry ↗ |
| Aug 18, 2023 | A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Participants With Duchenne… NCT03985878 · Duchenne Muscular Dystrophy Eteplirsen | SRPT Sarepta Therapeutics, Inc. | Phase 2 | Terminated | 15 | Aug 31, 2022 | Registry ↗ |
| Jun 15, 2023 | A Gene Transfer Therapy Study to Evaluate the Safety of SRP-9004 (Patidistrogene Bexoparvovec) in P… NCT01976091 · Limb-Girdle Muscular Dystrophy, Type 2D SRP-9004 | SRPT Sarepta Therapeutics, Inc. | Phase 1/2 | Completed | 6 | Mar 14, 2019 | Registry ↗ |
| Jul 6, 2022 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 (Ve… NCT03375255 · Muscular Dystrophy, Duchenne SRP-5051 | SRPT Sarepta Therapeutics, Inc. | Phase 1 | Completed | 15 | Aug 19, 2019 | Registry ↗ |
| Dec 9, 2021 | Study of Eteplirsen in Young Participants With Duchenne Muscular Dystrophy (DMD) Amenable to Exon 5… NCT03218995 · Duchenne Muscular Dystrophy Eteplirsen | SRPT Sarepta Therapeutics, Inc. | Phase 2 | Completed | 15 | Mar 10, 2021 | Registry ↗ |
| May 17, 2021 | Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystr… NCT02530905 · Duchenne Muscular Dystrophy SRP-4045, Placebo | SRPT Sarepta Therapeutics, Inc. | Phase 1 | Completed | 12 | Oct 3, 2018 | Registry ↗ |
| May 13, 2021 | rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies NCT02710500 · Dysferlinopathy rAAVrh74.MHCK7.DYSF.DV | SRPT Sarepta Therapeutics, Inc. | Phase 1 | Completed | 2 | Jul 2019 | Registry ↗ |
| Jan 25, 2021 | Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy NCT02420379 · Duchenne Muscular Dystrophy (DMD) eteplirsen | SRPT Sarepta Therapeutics, Inc. | Phase 2 | Completed | 33 | Dec 17, 2018 | Registry ↗ |
| Jan 25, 2021 | Study of Eteplirsen in DMD Patients NCT02255552 · Duchenne Muscular Dystrophy (DMD) eteplirsen | SRPT Sarepta Therapeutics, Inc. | Phase 3 | Completed | 109 | Jun 14, 2019 | Registry ↗ |
| Oct 19, 2020 | Phase I/II Study of SRP-4053 in DMD Patients NCT02310906 · Duchenne Muscular Dystrophy Placebo, SRP-4053 | SRPT Sarepta Therapeutics, Inc. | Phase 1/2 | Completed | 39 | Mar 25, 2019 | Registry ↗ |
| Mar 30, 2020 | Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy NCT02286947 · Muscular Dystrophy, Duchenne Eteplirsen | SRPT Sarepta Therapeutics, Inc. | Phase 2 | Completed | 24 | Apr 21, 2017 | Registry ↗ |
| Mar 30, 2020 | Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular… NCT01540409 · Duchenne Muscular Dystrophy (DMD) AVI-4658 (Eteplirsen) | SRPT Sarepta Therapeutics, Inc. | Phase 2 | Completed | 12 | Apr 15, 2016 | Registry ↗ |
| Mar 30, 2020 | Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy… NCT01396239 · Duchenne Muscular Dystrophy AVI-4658 (Eteplirsen), Placebo | SRPT Sarepta Therapeutics, Inc. | Phase 2 | Completed | 12 | Feb 2012 | Registry ↗ |
| Oct 6, 2015 | Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystro… NCT00844597 · Duchenne Muscular Dystrophy AVI-4658 for Injection | SRPT Sarepta Therapeutics, Inc. | Phase 1/2 | Completed | 19 | Jun 2010 | Registry ↗ |
39 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 8:04 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances